Metastatic breast cancers carry a 5-year survival prognosis of less than 20%. Thus, it is highly desirable to identify therapeutic strategies that specifically target both primary and metastatic tumors. It is generally accepted that epithelial-mesench . . .

HER2 (Epidermal Growth Factor Receptor Type 2) positive breast cancer accounts for 20-30 percent of cases and is associated with increased tumor cell proliferation, resistance to hormonal therapies and decreased patient survival. Trastuzumab (Hercepti . . .